Early use of J & J's Zytiga extends prostate cancer survival

CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news